๐ฐ Monitoring Recommendations News
Monitoring Recommendations News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Monitoring Recommendations. Real-time updates on events, politics, business and more.
October 14, 2021
/PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that the U.S. Food and Drug Administration (FDA) has accepted for priority...
September 30, 2021
Press release content from PR Newswire. The AP news staff was not involved in its creation.
August 21, 2021
Press release content from PR Newswire. The AP news staff was not involved in its creation.
July 20, 2021
Press release content from PR Newswire. The AP news staff was not involved in its creation. Japan Becomes First Country to Approve Regeneron Antibody Cocktail (casirivimab and imdevimab) for the Treatment of Mild to Moderate COVID-19 July 20, 2021 GMT TARRYTOWN, N.Y., July 20, 2021 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that Japanโs Ministry of Health, Labour and Welfare (MHLW) has approved Regeneronโs casirivimab and imdevimab antibody cocktail to tr...
June 4, 2021
/PRNewswire/ -- EUA supported by pivotal Phase 3 data showing 1,200 mg dose reduced risk of hospitalization or death by 70% Only antibody therapy currently...
April 12, 2021
Published: Apr 12, 2021 TARRYTOWN, N.Y., April 12, 2021 /PRNewswire/ -- REGEN-COV rapidly protected household contacts from exposure to SARS-CoV-2 at home, with 72% protection against symptomatic infections in the first week, and 93% in subsequent weeks Among individuals who developed symptomatic infections, REGEN-COV recipients cleared the virus faster and had much shorter symptom duration Regeneron will share data with U.S. FDA and request EUA expansion to include COVID prevention for app...
April 12, 2021
Share this article TARRYTOWN, N.Y., April 12, 2021 /PRNewswire/ -- Second Phase 3 trial undertaken in collaboration with NIAID to announce results today, both using subcutaneous administration of REGEN-COV in asymptomatic individuals without prior COVID-19 infection Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced positive data from a Phase 3 trial (2069B) of recently infected asymptomatic COVID-19 patients, evaluating REGEN-COVโข (casirivimab with imdevimab) 1,200 mg administere...
January 27, 2021
Columbia University researchers and Regeneron have independently confirmed findings; data included in bioRxiv paper and submitted for peer-reviewed publication Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that researchers in Dr. David Hos Columbia University lab and Regeneron scientists have independently confirmed that REGEN-COV TM (casirivimab and imdevimab antibody cocktail) successfully neutralizes the circulating SARS-CoV-2 variants first identified in the UK (B.1.1.7) a...
January 26, 2021
Reduction in overall infections seen within first week, with 100% prevention of symptomatic infections Markedly decreased levels and duration of viral shedding in asymptomatic infections that still occurred in REGEN-COV group Confirmatory Phase 3 results expected early in second quarter Potential application in people who need immediate protection or respond poorly to vaccination REGEN-COV 1,200 mg administered by subcutaneous injection, providing greater convenience and efficiency than inf...
December 30, 2020
TARRYTOWN, N.Y., Dec. 29, 2020 /PRNewswire/ --Phase 3 program in hospitalized patients to continue based on passing futility analysis on ability to reduce incidence of death or mechanical ventilation As in earlier outpatient trial, immune status when patients entered the trial was a strong predictor of viral load...